Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
The medicine was well tolerated, with no unexpected safety issue
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Facility designed to advance the next generation of imaging systems
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Subscribe To Our Newsletter & Stay Updated